Andrew H. Talal MD, MPH

Andrew Talal

Andrew H. Talal
MD, MPH

Professor

Department of Medicine

Jacobs School of Medicine & Biomedical Sciences

Specialty/Research Focus

Liver (Hepatology)

Contact Information
Clinical and Translational Research Center
875 Ellicott Street
Suite 6090
Buffalo, New York 14203
Phone: 716-961-9900
Fax: 716-854-1397
ahtalal@buffalo.edu
View map
View faculty website


Patient Care

This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.

View this physician on UBMD

Overview Research Publications Activities Latest News

Professional Summary:

I am a leading expert in liver disease. My work through UBMD has led to many improvement in treatment of patients with viral hepatitis and other forms of liver disease. We offer trial therapies to patients with liver disease if they meet the protocol criteria of our clinical trials. Our patient-care efforts include digital outreach: my colleagues and I co-authored an article for the inaugural issue of the patient-oriented online magazine “HCV Next.”

My lab has received multi-year funding for its research programs in translational and clinical research. During the course of our translational research, members of my lab and I developed techniques for animal and human liver sampling that will enable sorting of liver cells in order to understand drug distribution in the liver during treatment and to develop ways to measure liver drug concentration. These translational research techniques will enable physicians to base drug dosing on the data gathered from the site of antiviral action in the liver instead of measuring the plasma concentration that is more reflective of systemic exposure. This may be an important breakthrough because of the fine line between drug efficacy and toxicity: the techniques will help physicians pinpoint the precise amount of drug needed for maximum benefit to the patient.

In the area of clinical research, we are studying care models for viral hepatitis. We are conducting a study sponsored by the Centers for Disease Control and Prevention (CDC) Foundation to assess telemedicine to treat hepatitis C (HCV) in patients who are in treatment for substance use. By creating processes that simplify testing and improve provider and patient awareness and by expanding recommendations for HCV screening, patients can receive more timely care and treatment.

I teach GI fellows, residents and students in the outpatient setting. I am also very interested in mentoring, and I supervise residents and fellows in clinical research as well as in my laboratory. The enriching experience my trainees receive affords them excellent placement opportunities once their training is complete. A number of my former trainees have been listed as co-authors on manuscripts.

Education and Training:
  • Research Associate and Clinical Scholar, The Rockefeller University, Aaron Diamond AIDS Research Center (2000)
  • Fellowship, Medicine, Division of Gastroenterology, University of North Carolina (1996)
  • MPH, Epidemiology, University of North Carolina (1996)
  • Fellowship, Medicine, University of North Carolina (1995)
  • Internship, Internal Medicine, University of Iowa (1993)
  • MD, Internal Medicine, University of Texas Health Science Center (1990)
  • BA, Independent Major, Brown University (1986)

Employment:
  • Adjunct Professor of Medicine, Internal Medicine, University of Rochester School of Medicine (2014-present)
  • Founder and Director, UBMD Center for Clinical Care and Research in Liver Disease (2014-present)
  • Founder and Director, UBMD Internal Medicine Center for Clinical Care and Research in Liver Disease (2014-present)
  • Professor, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2012-present)
  • Adjunct Associate Professor of Medicine, Weill Cornell Medical College (2012–2019)
  • Corporate Medical Director, Gastroenterology, Kaleida Health System (2013–2015)
  • Chief of Gastroenterology, Erie County Medical Center (2012–2014)
  • Chief, Division of Gastroenterology, Hepatology and Nutrition, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2012–2014)
  • Adjunct Clinical Attending Physician, Beth Israel Medical Center (2010–2012)
  • Associate Attending Physician, New York Presbyterian Hospital (2005–2012)
  • Associate Professor of Medicine, Weill Cornell Medical College (2005–2012)
  • Associate Attending Physician, Rockefeller University Hospital (2001–2012)
  • Assistant Professor of Medicine, Weill Cornell Medical College (2000–2005)
  • Clinical Instructor, Department of Medicine, University of North Carolina (1993–1996)
See all (4 more)

Awards and Honors:
  • UB Exceptional Scholars Award 2020-2021 (2021)
  • Chancellor's Award for Excellence in Scholarship and Creative Activities (2020)
  • CTSI Clinical Research Achievement Award - 1st place (2018)
  • START Treatment & Recovery Centers (2016)
  • Buffalo's Health Care 50 (2013)
  • Clinical Infectious Diseases Award (2010)
  • Clinton Global Initiatives Award, William Clinton Foundation (2006)
  • Travel Award to American Society for Clinical Investigation Annual Meeting (2005)
  • Clinical Research Feasibility Funds Program Award (2003)
  • Mentored Physician-Scientist Development Award (1998)
  • Clinical Scholar Research Award (1996)
  • Young Investigators Award (1996)
  • Honors in Portuguese and Brazilian Studies (1986)
  • National Research Service Award

Research Expertise:
  • Liver disease

Grants and Sponsored Research:
  • December 2013–April 2028
    NIH/NIAID (Morse) HIV/AIDS Clinical Trial Unit
    Role: Co-Principal Investigator
  • July 2018–June 2025
    Troup Fund/Kaleida Health Foundation Liver Center of Western New York
    Troup Fund/Kaleida Health Foundation Liver Center of Western New York
    Role: Principal Investigator
    $3,067,590
  • November 2016–July 2024
    Patient-Centered HCV Care via Telemedicine for Individuals on Opiate Substitution Therapy: A Stepped Wedge Cluster Randomized Controlled Trial
    Patient-Centered Outcomes Research Institute (PCORI)
    Role: Principal Investigator
    $7,000,000
  • August 2020–June 2024
    NIH/NIDDK (Shapiro) Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
    Role: Co-Principal Investigator
  • January 2018–December 2023
    A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
    Intercept Pharmaceuticals
    Role: Principal Investigator
  • January 2015–December 2023
    A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
    Intercept Pharmaceutical
    Role: Principal Investigator
  • January 2019–December 2022
    A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (Eli Lilly and Company)
    Eli Lilly and Company
    Role: Principal Investigator
  • January 2019–December 2022
    A Phase 2B Randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (Bristol-Myers Squibb)
    Bristol-Myers Squibb
    Role: Principal Investigator
  • January 2019–December 2022
    A Phase 2B Randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis (Bristol-Myers Squibb)
    Bristol-Myers Squibb
    Role: Principal Investigator
  • January 2018–December 2021
    Focus Award
    Gilead Science, Inc
    Role: Co-Principal Investigator
    $315,008
  • December 2013–April 2021
    HIV/AIDS Clinical Trials Unit
    ACTG sponsored by the National Institute of Allergy and Infectious Disease (NIAID) (University of Rochester)
    Role: Co-Investigator
  • April 2018–February 2021
    Point of Care Education Increase Substance Users Initiation of HCV Care among Persons With Substance Use Disorders Investigator-initiated, industry sponsored (Merck and Co.)
    Merck and Co.
    Role: Principal Investigator
    $74,184
  • November 2018–September 2019
    Best practice model to screen for Hepatitis C and HIV
    Gilead Sciences
    Role: Co-Investigator
    $315,000
  • November 2016–October 2018
    TLR5 Agonist Entolimod as Immunotherapy for Liver Cancer and Hepatitis B Virus Infection
    The V Foundation for Cancer Research
    Role: Co-Principal Investigator
    $399,716
  • October 2015–September 2018
    BD Hubs: Collaborative Proposal: Northeast: The Northeast Big Data Innovation Hub
    National Science Foundation
    Role: Contributor
    $1,250,000
  • July 2016–June 2017
    Pharmacokinetics of Methadone in HIV/HCV Infected Patients with and without Liver Fibrosis
    NIH/NIDA
    Role: Co-Investigator
    $94,532
  • June 2015–June 2017
    An Exploratory Study to Evaluate the Kinetics of Viral Load Decline with Ombitasavir/AVT-450/Ritonavir and Dasabuvir Therapy with Low-Dose Ribavirin (RBV), Full Dose RBV or RBV Add-on in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus
    Abbvie Pharmaceuticals
    Role: Principal Investigator
  • September 2014–December 2015
    Intrahepatic ABT450 Concentration in Preclinical Models
    Abbvie Pharmaceuticals
    Role: Principal Investigator
  • February 2013–December 2015
    A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-like 2 (LOXL 2) in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary t
    Gilead Sciences
    Role: Principal Investigator
  • February 2013–December 2015
    A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-like 2 (LOXL 2) in Subjects with Compensated Cirrhosis Secondary to NASH.
    Gilead Sciences
    Role: Principal Investigator
  • July 2014–October 2015
    A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis and Child-Pugh (CP)-B Hepatic Insufficiency
    Merck and Co
    Role: Principal Investigator
  • April 2012–December 2014
    Prevention, Evaluation and Treatment of HCV in Opiate Agonist Treatment Settings (PET-C)
    CDC Foundation/VHAC
    Role: Principal Investigator
  • November 2011–December 2014
    Phase 2a, Pilot, Open Label Trial Evaluating the Safety, Tolerability and Pharmacodynamic Effects of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-like Molecule 2 (LOXL2) in Subjects with Fibrosis of the Liver.
    Gilead Sciences
    Role: Principal Investigator
  • January 2010–January 2012
    Risks Factors for AID among IV Drug users(1R21DA030272-01)
    NIH/NIDA (Levy)
    Role: Co-Investigator
  • January 2010–January 2012
    Assessment by Meta-analysis of Treatment of Addiction as a Determinant of Successful Treatment Response for Hepatitis C Virus Infection in Drug Users
    Merck and Company
    Role: Co-Investigator
  • January 2006–January 2012
    Adult AIDS Clin Trials Program-Cornell Clinical Trials Unit(U01-AI-69419)
    NIH/NIAID (Gulick)
    Role: Co-Investigator
  • January 2004–January 2009
    Acute HCV Infection in Injection Drug Users
    NIH/R01
    Role: Co-Investigator
  • April 2017
    Role of Contingency Management in the Treatment of Youth and Their Parents in a Pediatric Tertiary Care Weight Management Program
    University at Buffalo Clinical and Translational Science Institute
    Role: Co-Investigator
    $42,000
See all (18 more)

Journal Articles:

See all (143 more)

Abstracts:

  • Dimova RB, Martinez AD, Weinberg E, Drobnik A, Talal AH. (2015) Age and risk factor-based serologic screening for hepatitis C virus among an urban high-risk population. Hepatology, (Oct) 1098A-1098A
  • Zeremski M, Dimova RB, Pillardy J,De Jong YP, Jacobson IM, Talal AH. (2015) Fibrosis progression in patients with chronic hepatitis C virus infection. Hepatology, (Oct) 1106A-1106A
  • Talal AH, Furlage R, Woolwine-Cunningham Y. (2015) Hepatocyte isolation from liver fine needle aspiration and core needle biopsy. Hepatoloogy, (Oct) 379A-379A
  • Sehgal M, Zeremski M, Talal AH, Khan ZK, Capocasale R, Philip R, Jain P. (2015) Host genetic factors and miRNA-linked dendritic cell responses associated with the outcome of treatment response in HIV-1/HCV co-infected individuals. J Neurovirol, (Jun) S68-S69
  • Feld JJ, Dore GJ, Wyles D, Lawitz E,Talal AH, Ball G, Dumas EO, Jacobson IM. (2015) Plasma Interferon-y-inducible protein 10 (IP-10) and response to interferon-free direct-acting antiviral therapy in HCV genotype-1 infected patients with and without cirrhosis. Gastroenterology, (Apr) S1087-S1098
  • Zeremski M, Dimova RB, Zavala R, Kritz S, Lin M, Smith BD, Zibbell J, Talal AH. (2014) Hepatitis C virus related knowledge and willingness to receive treatment among patients on methadone maintenance. J Hepatol, (Apr) S483-484

Professional Memberships:
  • American Association of Immunologists (2004–2010)
  • American Association for the Study of Liver Diseases (2004–present)
  • American College of Physicians (Fellow, American College of Physicians) (2004–present)
  • American Association for the Advancement of Science (2001–2010)
  • American College of Physicians (Third Place, ACP Clinical Vignette Competition) (1993)
  • American College of Gastroenterology (1993–present)
  • American College of Physicians (1992–2004)
  • American Gastroenterological Association (1992–present)

Presentations:
  • "Facilitated Telemedicine for Underserved Populations: A Stepped Wedge Trial of Hepatitis C Treatment" Pathways Buffalo of the Catholic Health System (2024)
  • "Facilitated Telemedicine for Underserved Populations: A Stepped Wedge Trial of Hepatitis C Treatment" Clinical Education Initiative of the New York State Department of Health AIDS Institute, Mt Sinai Medical Center (2023)
  • "Facilitated Telemedicine for Underserved Populations: A Stepped Wedge Trial of Hepatitis C Treatment" University at Buffalo Infectious Diseases Grand Rounds (2023)
  • "Hepatitis C Virus Screening, Diagnostics, and Elimination" Global Virus Network Short Course in Virology (2023)
  • "Facilitated Telemedicine to Promote Hepatitis C Elimination" New York State Hepatitis C Virus Learning Collaborative for Substance Use Disorder Treatment Programs (2022)
  • "Facilitated Telemedicine to Promote Hepatitis C Elimination" New York State Hepatitis C Virus Learning Collaborative for Substance Use Disorder Treatment Programs (2022)
  • "Facilitated Telemedicine to Promote Hepatitis C Elimination, Eliminating Hepatitis C among Persons with Opioid Use Disorder" AATOD Preconference Symposium (2022)
  • "Facilitated Telemedicine to Promote Hepatitis C Elimination. Eliminating Hepatitis C among Persons with Opioid Use Disorder" AATOD Preconference Symposium (2022)
  • "Facilitated Telemedicine to Promote Hepatitis C Elimination. Innovations in Rural Telehealth for New York: Addressing Social Determinants of Health" Virtual (2022)
  • "Facilitated Telemedicine to Promote Hepatitis C Elimination. Innovations in Rural Telehealth for New York: Addressing Social Determinants of Health." Virtual (2022)
  • "Hepatitis C Care through Telemedicine to Promote Elimination" Clinical Education Initiative of the New York State Department of Health AIDS Institute, Mt. Sinai Medical Center (2022)
  • "Hepatitis C Care through Telemedicine to Promote Elimination" Clinical Education Initiative of the New York State Department of Health AIDS Institute, Mt. Sinai Medical Center (2022)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV- Treatment Expansion in High-risk Communities" Virtual (2022)
  • "HCV Elimination in the U.S. Insights from New York State" Alliance for Patient Access (2022)
  • "HCV Elimination in the U.S. Insights from New York State, Alliance for Patient Access" (2022)
  • "Key Considerations for HCV Elimination in the U.S." Housing Works HCV Training Seminar (2022)
  • "Key Considerations for HCV Elimination in the U.S." Housing Works HCV Training Seminar (2022)
  • "Update on Hepatocellular Carcinoma for the Community" Virtual CME Saturday (2022)
  • "Update on Hepatocellular Carcinoma for the Community" Virtual CME Saturday (2022)
  • "Key Consideration for HCV Elimination in the U.S." HRSA Rural Telehealth Consortium Meeting (2022)
  • "Key Considerations for HCV Elimination in the U.S." HRSA Rural Telehealth Consortium Meeting (2022)
  • "Key Considerations for HCV Elimination in the U.S." AETC/ID Thursday Noon Seminar Series, Downstate Medical Center (2021)
  • "Key Considerations for HCV Elimination in the U.S." Catholic Health System Saturday CME Series (2021)
  • "Key Considerations for HCV Elimination in the U.S." National AIDS Treatment Advocacy Project (2021)
  • "Patient-Centered, Integrated Telemedicine for the Treatment of Hepatitis C Virus in Opioid Treatment Programs. Establishing Comprehensive Prevention and Treatment Services for People Who Use Drugs" NASTAD Virtual Learning Collaborative (2021)
  • "Triple E for HCV: Treatment Expansion in High-risk Communities. Engagement, Education and Eradication of HCV" Pathways Buffalo, Virtual (2021)
  • "Building a Sustainable Telehealth Program" Webinar, Aspire Technologies (2021)
  • "Treating Substance Users for HCV via Telemedicine: Implementation and Engagement Considerations" Clinical Director's Network, Virtual (2021)
  • "Triple E for HCV: Engagement, Education and Eradication" Satellite Symposium Series, American Society of Addiction Medicine Conference (2021)
  • "Virtual Integration of Behavioral and medical treatment via telemedicine" Rural Communities Affected by Opioid Injection Drug Epidemics Telehealth Intervention Workgroup (2021)
  • "Virtual Integration of Behavioral and medical treatment via telemedicine" Addiction Technology Transfer Center Network HCV Learning Community (2020)
  • "Hepatitis C Telehealth Services in Harm Reduction Settings Virtual Panel" Virtual Panel (2020)
  • "Triple E for HCV: Engagement, Education and Eradication" National Conference on Correctional Health Care (2020)
  • "Building Capacity for Hepatitis C Treatment at Opioid Treatment Programs On-site and via Telemedicine, New York City" Final Presentation for HBV and HCV Cascades of Care Grant sponsored by Center for Disease Control (2020)
  • "Update on Liver Diseases: New Opportunities for Detection, Patient Engagement and Treatment" EHIV/ID Thursday Noon Seminar Series, Downstate Medical Center, Brooklyn, NY (2020)
  • "Telemedicine to Increase Access to Buprenorphine and Hepatitis C Treatment: Where Do We Go From Here?" New York State Hepatitis C and Drug User Health Conference (2020)
  • "Triple E for HCV-Engagement, Treatment Expansion in High-Risk Communities" Oriana House/ Rigel House, Marietta, OH (2020)
  • "Overview of NYS HCV Telehealth Workgroup" Hep Free NYC (2020)
  • "Medical and Psychosocial Aspects of Integrated HCV and SUD Treatment" NYS Telehealth Workgroup (2020)
  • "Telehealth Practice Training" START Treatment & Recovery Centers, Brooklyn, NY (2020)
  • "Hepatitis C Virus Elimination in Opioid Treatment Programs in New York State" Update to AbbVie, Inc (2020)
  • "Triple E for HCV-Engagement, Education, and Eradication of HCV-Treatment Expansion in High-Risk Communities" Oriana House/ Rigel House, Marietta, OH (2020)
  • "Nonalcoholic Fatty Liver Disease" Diabetes and Endocrinology Center of Western New York, Williamsville, NY (2020)
  • "Patient-Centered Hepatitis C Virus (HCV) Care via Telemedicine for Individuals on Opiate Agonist Therapy: Telemedicine Arm" Strong Recovery, Rochester, NY (2020)
  • "Buffalo B.O.O.T.S.-Bringing Outreach on the Streets" Presentation to City of Buffalo Common Council (2019)
  • "HCV Echo-Patient Screening" Chronic Liver Disease Foundation (2019)
  • "HCV Symposium to Explore Obstacles to HCV Prescribing in Syracuse" (2019)
  • "Telemedicine for HCV Care in Substance Users" NASTAD Hepatitis Testing Learning Collaborative Reverse Site Visit, Albany, NY (2019)
  • "Triple E for HCV Satellite Symposium Series: Engagement, Education, and Eradication" National Commission on Correctional Healthcare Annual Conference, Ft. Lauderdale, FL (2019)
  • "Triple E for HCV Satellite Symposium Series: Engagement, Education, and Eradication" American Association for the Treatment of Opioid Dependence, Walt Disney World, FL (2019)
  • "Engagement of Opioid Use Disorder Patients into Hepatitis C Virus Care (HCV) via Telemedicine" Catholic Health System Saturday CME Series, Buffalo, NY (2019)
  • "HCV Ask the Professor National Call w/Dr. Talal" AbbVie, Inc (2019)
  • "HCV Echo-Elimination" Chronic Liver Disease Foundation (2019)
  • "New Partner Perspective: Routinizing HIV/HCV Screening and Linkage to Care in a Challenging Environment-Progress, Challenges, and Opportunities for Building Best Practices" Focus New York Partner’s Meeting, Albany NY (2019)
  • "Provider Perspective: USPSTF Draft Recommendations on HCV Testing" Focus New York Partner’s Meeting, Albany NY (2019)
  • "Teleconsultation for liver transplants" University of Rochester Liver Transplant Conference, Rochester, NY (2019)
  • "Triple E for HCV-Engagement, Education, and Eradication of HCV-Treatment Expansion in High-Risk Communities" Strong Recovery, Rochester, NY (2019)
  • "The State of Hepatitis C in the Buffalo Region" Presentation to City of Buffalo Common Council (2019)
  • "Innovative Strategies to Eliminate HCV" CDN Webinar (2019)
  • "Triple E for HCV-Engagement, Education, and Eradication of HCV-Treatment Expansion in Appalachia" CLDF Webinar (2019)
  • "Engagement of Persons on Opioid Substitution Therapy into Care for HCV by Telemedicine" Catholic Health Services Resident’s Conference, Buffalo, NY (2019)
  • "Innovative Strategies to Eliminate HCV" American Society of Microbiology Clinical Virology Symposium, Savannah, GA (2019)
  • "Integration of Hepatitis C Treatment into Opioid Treatment Programs via Telemedicine" National Academy of Sciences, Engineering, and Medicine, Washington, DC (2019)
  • "Triple E for HCV-Engagement, Education, and Eradication of HCV-Treatment Expansion in Appalachia" Cornerstone Family Healthcare, Newberg, NY (2019)
  • "Triple E for HCV-Engagement, Education, and Eradication of HCV-Treatment Expansion in Appalachia" Binghamton, NY (2019)
  • "HCV Management and Treatment Update" Crouse Health, Syracuse, NY (2019)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Symposium at ASAM 50th Annual Conference, Orlando, FL (2019)
  • "Telemedicine for HCV Care in Substance Users" Empire Liver Foundation, New York, NY (2019)
  • "Engagement of Persons on Opioid Substitution Therapy into Care for HCV by Telemedicine" Erie County Opioid Task Force and Treatment Provider Work Group, Buffalo, NY (2019)
  • "WNY Harm Reduction Conference" WNY Harm Reduction Conference, Evergreen Health, Buffalo, NY (2018)
  • "HIV and Hepatitis C Pharmacy Symposium: Expanding the Role of the Pharmacist" Mount Sinai – Institute for Advanced Medicine, Buffalo, NY (2018)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Crouse Health, Syracuse, NY (2018)
  • "Engagement of Persons on Opioid Substitution Therapy into Care for HCV by Telemedicine" Disaster Preparedness and Response: Increasing Capacity through Shared Knowledge, a Case for Care Integration, San Juan, PR (2018)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" START Treatment & Recovery Center’s Fort Greene Clinic, Brooklyn, NY (2018)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" START Treatment & Recovery Center’s East New York Clinic, Brooklyn, NY (2018)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Cornerstone Family Healthcare, Newburgh, NY (2018)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Strong Recovery Chemical Dependency, Rochester, NY (2018)
  • "Telemedicine-Based Hepatitis Treatment in New York OTPs" National Association of State Alcohol and Drug Abuse Directors, Inc. Webinar (2018)
  • "Engagement of Persons on Opioid Substitution Therapy into Care for HCV by Telemedicine" University of Kentucky Division of GI Seminar, Lexington, KY (2018)
  • "Linkage to HCV Care via Telemedicine for OST Patients" Portuguese Liver Congress, Figueroa de foz, Portugal (2018)
  • "Patient-Centered Approaches to Engagement and Retention of Persons with Substance Use Disorders into HCV Care" Conference Chair (2018)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" American Association for the Treatment of Opioid Dependence, New York, NY (2018)
  • "Engagement of Persons on Opioid Substitution Therapy into Care for HCV by Telemedicine" Seminar, New York City Department of Health and Mental Hygiene, Queens, NY (2018)
  • "Virtual Integration of Hepatitis C and Substance Use Treatment" Telehealth Learning Collaborative, Webinar (2018)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" National Conference on Correctional Health, Chicago, IL (2017)
  • "HCV Diagnostic and Viral Genetic Considerations among PWIDs" Abbott Diagnostics Annual Investigator Meeting, Washington, DC (2017)
  • "Telemedicine in Clinical Care and as a Tool in Addiction Medicine" Addiction Conference, 40th Anniversary of Society for Alcoholism and Other Addictions, Reykjavik, Iceland (2017)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" East New York Clinic, START Treatment & Recovery Centers, Brooklyn, NY (2017)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Addiction Medicine Track, Building Bridges-Alcoholism & Substance Abuse Providers of New York State (ASAP) Annual Meeting, Buffalo, NY (2017)
  • "Virtual Integration of Hepatitis C and Substance Use Treatment" Alcoholism & Substance Abuse Providers of New York State 18th Annual Conference, Buffalo, NY (2017)
  • "Virtual Integration of Hepatitis C and Substance Use Treatment" Nursing Track, Building Bridges-Alcoholism & Substance Abuse Providers of New York State (ASAP) Annual Meeting, Buffalo, NY (2017)
  • "Virtual Integration of Hepatitis C and Substance Use Treatment" Western NY HIV/STD/VH Public Health Consortium Meeting, Warsaw, NY (2017)
  • "Virtual Integration of Hepatitis C and Substance Use Treatment" Finger Lakes HIV/STD/VH Public Health Consortium Meeting, Canandaigua, NY (2017)
  • "How to Manage HCV after Virtually integrated HCV and Substance Use Treatments are Successful?" START Treatment & Recovery Centers, Brooklyn NY (2017)
  • "How to Manage HCV after Virtually integrated HCV and Substance Use Treatments are Successful?" Internal Medicine Conference, Omaha, NE; University of Nebraska Medical Center (2017)
  • "Virtual Integration of Hepatitis C and Substance Use Treatment" Merck Stand Alone Scientific Symposium (SASS), Barcelona, Spain (2017)
  • "Patient-Centered HCV Care via Telemedicine for Individuals on Opiate Substitution Therapy: A Stepped-wedge Cluster Randomized Controlled Trial" 2017 Annual Research Meeting, Academy Health, New Orleans, LA (2017)
  • "Telemedicine Treatment Approaches for Hepatitis C Virus (HCV) Management for Individuals on Opioid Agonist Treatment" UB Family Medicine Faculty Development Series-Drug Addiction, Buffalo, NY; University at Buffalo (2017)
  • "Virtual Integration of Hepatitis C and Substance Use Treatment" New York State Department of Health, AIDS Institute, Albany, NY (2017)
  • "Virtual Integration of Hepatitis C and Substance Use Treatment" Merck Global Therapeutic Expert Forum, Jersey City, NJ (2017)
  • "Telemedicine Treatment Approaches for Hepatitis C Virus (HCV) Management for Individuals on Opioid Agonist Treatment" Annual Joint Meeting Western NY & Finger Lakes HIV/STD Viral Hepatitis Public Health Consortia. Rochester, NY (2017)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Spring 2017 meeting of Western New York branch of American Society for Microbiology, Buffalo, NY; University at Buffalo Center for Tomorrow (2017)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Crouse Hospital Chemical Dependency Unit, Syracuse, NY (2017)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Strong Recovery Chemical Dependency Unit, Rochester, NY (2017)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Third Horizon Clinic, New York, NY (2017)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Cornerstone Family Healthcare, Newburgh, NY (2017)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" DART Clinic, Buffalo, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Fort Greene Clinic, Brooklyn, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Bushwick Clinic, Brooklyn, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Benny J. Primm Center for Health Lifestyles, New York, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" East New York Clinic, Brooklyn, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Highbridge Clinic, New York, NY (2016)
  • "AASLD Basic Science Symposium on Liver Immunology: Fine Needle Aspiration (FNA) for Assessment of Intrahepatic Immunity and Other Things" AASLD Basic Science Symposium on Liver Immunology, Boston, MA (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" CDN Webinar, New York, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Dole Clinic, Brooklyn, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Gouverneur Clinic, New York, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Cumberland Clinic, Brooklyn, NY (2016)
  • "Telemedicine Treatment Approaches for Hepatitis C Virus (HCV) Management for Individuals on Opioid Agonist Treatment" UB Family Medicine Faculty Development Series-Drug Addiction; University at Buffalo (2016)
  • "Telemedicine Treatment Approaches for Hepatitis C Virus (HCV) Management for Individuals on Opioid Agonist Treatment" Hepcure Webinar (2016)
  • "Telemedicine Treatment Approaches for Hepatitis C Virus (HCV) Management for Individuals on Opioid Agonist Treatment. S18: Prevention and Management of Hepatitis C Virus Infection in People Who Use Drugs" International Society of Addiction Medicine Annual Meeting, Montreal, Quebec (2016)
  • "Telemedicine Treatment of HCV Among Patients on Opiate Agonist Therapy" University of Rochester Infectious Diseases Division Research Conference (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Health Alliance of the Hudson Valley, Kingston, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" American Association for the Treatment of Opioid Dependence, Baltimore, MD (2016)
  • "Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus (HCV) Management for Individuals on Opiate Agonist Treatment" NYC HCV Initiative Expert Input Forum; Merck and Co (2016)
  • "Telemedicine Treatment for Hepatitis C Virus (HCV) for Patients on Methadone Maintenance" Addictions Medicine and Recovery Conference; Health Alliance of the Hudson Valley; Westchester Medical Center (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Pathways Drug Abuse Treatment, Buffalo, NY (2016)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV among Patients with Substance Use Disorders" Hazelden Betty Ford Foundation, Rancho Mirage, CA (2016)
  • "Patient-Centered HCV Care via Telemedicine for Individuals on Opiate Substitution Therapy: A Stepped Wedge Cluster Randomized Controlled Trial" Organizer, Organizational Meeting for PCORI Award, New York, NY (2016)
  • "Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders" Center for Comprehensive Health Practice, New York, NY (2016)
  • "Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders" NYU Lutheran Family Health Center, Brooklyn, NY (2016)
  • "So I have Achieved an SVR. What Now?" Merck Global Therapeutic Expert Forum, Management of Persons with Substance Use Disorders After Viral Eradication, Jersey City, NJ (2016)
  • "Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders" START Treatment and Recovery Centers, Brooklyn, NY (2016)
  • "Increasing Access to Hepatitis C Treatment for Opiate-Maintained Patients via Telemedicine" New York State 2016 Clinical Conference on HIV and Hepatitis C: Advancing Care Through Knowledge, Policy and Implementation, Rochester, NY (2016)
  • "Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders" Addiction Medicine Grand Rounds, Horizon Village, Buffalo, NY; Horizon Village (2016)
  • "Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders" Center for Comprehensive Health Practice, New York, NY (2015)
  • "Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders" Strong Recovery, University of Rochester, NY (2015)
  • "HCV Workforce Development in the Drug and Alcohol Sector" 4th International Symposium on Hepatitis Care in Substance Users, Sydney, NSW, Australia; ; Merck Satellite Symposium (2015)
  • "Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders" START Treatment and Recovery Centers, Brooklyn, NY (2015)
  • "Development of Liver Research and Clinical Care in Jamaica" University of the West Indies, Mona Campus, Kingston, Jamaica (2015)
  • "Liver Diseases Overview" Symposium Chair/Presenter, The Liver Summit, Buffalo, NY; Chronic Liver Disease Foundation (2015)
  • "Triple E for HCV: Engagement, Education and Eradication of HCV Among Patients with Substance Use Disorders" Addiction Medicine Grand Rounds, Horizon Village, Buffalo, NY; Horizon Village (2015)
  • "Clinical and Translational Research in Hepatology" Keynote Speaker, 10th Annual Austin Flint & John J. O‘Brien Research Symposium (2015)
  • "HCV Monoinfection: The End of the Beginning or the Beginning of the End" Advances in HCV 2015 Conference (2015)
  • "Challenges to Hepatitis C Virus (HCV) Care via Telemedicine for Individuals on Opiate Agonist Therapy" 2015 ATA Annual Telemedicine Meeting and Trade Show, Los Angeles, CA (2015)
  • "Opening the Door to Understanding the Liver‘s Role in Pharmacology" 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy (2015)
  • "Prevention, Evaluation and Treatment of HCV: The Telemedicine Phase" START Treatment and Recovery Centers, New York, NY (2015)
  • "Integrating Hepatitis Therapy in the Nation's OTPs; The Role of OTPs in Preventing, Treating and Educating on HCV and HIV" American Association for the Treatment of Opiod Dependence (AATOD) National Conference, Atlanta, GA; Substance Abuse Mental Health Services Administration (2015)
  • "Journey Toward HCV Eradication in Substance Dependent Populations" Viral Hepatitis Grand Rounds, Philadelphia, PA; University of Pennsylvani (2015)
  • "Role of Opiate Treatment Program in Prevention, Treatment and Education of HCV and HIV" National Association of State Alcohol and Drug Abuse Directors, Washington, DC; ; HIV Coordinators Quarterly Conference Call (2015)
  • "Liver Diseases Overview" The Liver Summit, Buffalo, NY; Chronic Liver Disease Foundation (2014)
  • "Update on Treatment of Hepatitis C Virus infection: Focus on Cirrhosis and Portal Hypertension" 8th Annual VIA Symposium: Endovascular Advances, Buffalo, NY; VIA Foundation (2014)
  • "Update in Treatment of Hepatitis C Virus" Mercy Hospital of Buffalo Saturday CME Conference, Buffalo, NY; Mercy Hospital of Buffalo (2014)
  • "Now is the Time: the Mandate to Treat Hepatitis C" Mini Medical School, Buffalo, NY; University at Buffalo (2014)
  • "HCV direct acting antiviral assays in liver tissue clinical pharmacology biomatrices for HIV, HCV and TB-adherence" Prevention and Treatment Workshop, AIDS Clinical Trials Group Annual Meeting (2014)
  • "What’s New in Hepatitis C Screening and Treatment" Albany Medical College 15th Annual HIV Clinical Care Symposium, Troy, NY; Co-sponsored by the New York/New Jersey AIDS Education and Training Center and New York State‘s HIV Clinical Education Initiative; Albany Medical College (2014)
  • "Peripheral and Intrahepatic viral kinetics and host immune responses in HCV during antiviral therapy" Case Western Reserve University, Cleveland, OH; Joint Seminar Series; World Health Interest Group and Division of Infectious Disease & HIV Medicine (2014)
  • "Hepatitis C Virus (HCV) Related Knowledge and Willingness to Receive Treatment Among Patients on Methadone Maintenance" EASLD International Liver Congress, London, UK; European Association for the Study of Liver Disease (2014)
  • "Intrahepatic Sampling to Understand Viral and Drug Kinetics using Fine Needle Aspiration" HEP DART 2013: Frontiers in Drug Development for Viral Hepatitis, Kohala Coast, HI (2013)
  • "Hepatitis C in 2013: Where Are We, Who Should We Treat and With What Should We Treat" ASAM Annual Medical-Scientific Conference, Chicago, IL; American Society of Addiction Medicine; Session on Hepatitis C in 2013 (2013)
  • "Hepatitis C Treatment in Drug Users: Is It Finally Appearing on the Radar?" Yale Liver Center Research Seminar, New Haven, CT; Yale University Medical Center (2013)
  • "How to Approach the Paradigm in the Addiction Population" The New Paradigm of HCV Therapy - Integration of Oral Therapies into Best Practices, Boston, MA; Harvard Medical School; Liver Institute and Foundation for Education and Research (2013)
  • "Addressing HCV Clinical Gaps Among Special Patient Populations" HIV Grand Rounds, VA Western NY, Buffalo, NY; VA Western New York (2011)
  • "Addressing HCV Clinical Gaps Among Special Patient Populations" HIV Grand Rounds, Roosevelt Hospital Center, New York, NY; Roosevelt Hospital Center, New York, NY (2011)
  • "Clinical management of HCV in patients with and without HIV" Physicians Research Network; New York University (2011)
  • "HCV Management in Patients on Opiate Agonist Therapy via Telemedicine: A Non-comparative, Feasibility Study." Abbott Molecular Diagnostics Grand Rounds, Des Plaines IL (2011)
  • "Lessons Learned from Liver Fibrosis Trials" Gilead Sciences Fibrosis Advisory Board, South Francisco, CA (2011)
  • "New Developments in the Treatment of Chronic Hepatitis C" Addiction Research and Treatment Corporation, Brooklyn, NY (2011)
  • "New Developments in the Treatment of Chronic Hepatitis C" Infectious Disease Update 2011, New York, NY; Weill Cornell Medical College (2011)
  • "New Developments in the Treatment of Chronic Hepatitis C." New York/New JerseyAIDS Education and Training Center Faculty Development (2011)
  • "Prevention, Evaluation and Treatment for HCV Management" Opicare Advisory Board Meeting, Brussels, Belgium (2011)
  • "Prevention, Evaluation and Treatment of Hepatitis C in Opiate Agonist Treatment Settings: PET-C HCV Management" Steering Committee Meeting, Viral Hepatitis Action Coalition: Models of Prevention, Treatment and Care (2011)
  • "Treating HCV/HIV Coinfection: Outcomes and Impact on Disease Status" NY Methodist Hospital (2011)
  • "Treatment of Chronic Hepatitis C in HIV infection, New Advances in Hep C Therapy: The World is Changing" NATAP Forum; New York University School of Medicine, New York, NY (2011)
  • "Can we ever get to a world without interferon?" Hepatitis C Global Therapeutic Expert Forum, Dallas, TX (2010)
  • "Chemokines – A View into Virus-Host Interactions" Mt Sinai School of Medicine, New York, NY (2010)
  • "Clinical Applications in HCV: Steve, 36-Year-Old with Previous Injection Drug Use (IDU)" Orange CA, Anaheim CA, and San Diego, CA (2010)
  • "New Horizons in the Treatment of Hepatitis C" New York/New Jersey AIDS Education and Training Center Faculty Development, New Platz, NY (2010)
  • "New Horizons in the Treatment of Hepatitis C." Addiction Research and Treatment Corporation, Brooklyn, NY (2010)
  • "Patient-centered approaches to Hepatitis C management" Molecular Center of Excellence Alliance, Philadelphia, PA (2010)
  • "Treatment of the IVDU Patient Population: Outcomes from a Multidisciplinary Approach to Treatment, Genentech" Genentech (2010)
  • "Treatment of the IVDU Patient Population: Outcomes from Multidisciplinary Approach to Treatment" Opicare Advisory Board Meeting, Zurich, Switzerland (2010)
  • "Chemokines – A View into Virus-Host Interactions" XVI Annual Viral Hepatitis B and C Meeting, Athens, Greece; XVI Annual Viral Hepatitis B and C Meeting, Athens, Greece (2009)
  • "Predictive Factors of Response to the Treatment of HCV" Brookdale Hospital Center, Brooklyn, NY (2009)
  • "Predictive Factors of Response to the Treatment of HCV" Wykoff Hospital Center, Brooklyn, NY; Wykoff Hospital Center, Brooklyn, NY (2009)
  • "Triple E for HCV: Engagement, Education, and Eradication of HCV - Treatment Expansion in High-risk Communities" Virtual
See all (175 more)

Service Activities:
  • Patient-Centered Outcomes Research Institute Cycle 3 2023: Dissemination and Implementation Funding Announcement; Scientific reviewer (2023–present)
  • Special Emphasis Panel ZDK1 GRB-S (M3), Liver Cirrhosis Network: Clinical Research Centers (RFA-DK-20-003) (2021)
  • United University Professions, Buffalo HSC Chapter; Elected Senator (2021–2023)
  • University at Buffalo; Ad Hoc Tenure Review Committee Member (2021–present)
  • New York State Hepatitis C Virus Infection Guidelines Committee; Member (2021–present)
  • NYS Hepatitis C Telemedicine Workgroup; Chair (2020–2021)
  • National Institute of Health; Editorial Board: Reviewer (2017–present)
  • Frawley Fellowship; Editorial Board: Reviewer (2017–present)
  • Special Emphasis Panel: Elucidating HIV and HIV Treatment;; Ad Hoc Reviewer (2016)
  • Digestive Diseases and Nutrition C Subcommittee;; Ad Hoc Reviewer (2016)
  • NIH Special Emphasis Panel: HIV and Viral Hepatitis;; Chair (2016)
  • University of Buffalo Ad Hoc Qualified Promotions Committee to Clinical Educator and Volunteer ranks,non-tenure.; Member (2016–present)
  • RFA-DK-14-019: Studies of HIV in Digestive Diseases;; Ad Hoc Reviewer (2015–present)
  • HCV Education Initiative for Persons with Substance Use Disorders: "Triple E for HCV", Chronic Liver Disease Foundation; Chair (2015–present)
  • Research in Hepatitis and Chronic Liver Diseases; Editorial Board Member (2014–present)
  • Aids Clinical Trials Group (ACTG) Hepatitis Transformative Science Group ACTG HEP TSG; Member (2014–2015)
  • American Association for the Study of Liver Diseases Abstract Reviewer, Digestive Disease Week 2014; Ad Hoc Reviewer (2014)
  • HCV Next (SLACK Inc. publications); Editorial Board Member (2014–present)
  • Advisory Council for the UB Clinical Research Center/Clinical Trials Office; Member (2014–present)
  • Co-moderator, Early Morning Workshop (EMW-2) HCV Replication, The Liver Meeting 2013, Washington, DC Co-moderator, Early Morning Workshop (EMW-2) HCV Replication, The Liver Meeting 2013, Washington, DC; Moderator (2013)
  • Addiction Research and Treatment Corporation (ARTC); Advisory Board (2013–present)
  • NIDDK-C Subcommittee;; Ad Hoc Reviewer (2012–present)
  • Special Emphasis Panel;; External Reviewer (2011–present)
  • NIDDK R01 Ancillary Study Grant Review;; Grant Reviewer (2011–present)
  • Journal of Hepatology; Editorial Board Member (2010–2015)
  • Hepatic Medicine: Evidence and Research (Honorary); Editorial Board Member (2008–present)
  • Translational Research; Editorial Board Member (2006–2014)
  • Empire Clinical Research Investigator Program Review Panel, New York Presbyterian Hospital; Member (2003–2004)
  • New York Presbyterian Hosp-Weill-Cornell Medical College Children’s Clinical Research Center; Reviewer (2003–present)
  • Transplantation; Ad Hoc Reviewer (1998–present)
  • Virology; Ad Hoc Reviewer (1998–present)
  • Gastroenterology; Ad Hoc Reviewer (1998–present)
  • Hepatology; Ad Hoc Reviewer (1998–present)
  • HIV Clinical Trials; Ad Hoc Reviewer (1998–present)
  • Journal of Interferon and Cytokine Research; Ad Hoc Reviewer (1998–present)
  • Journal of Viral Hepatitis; Ad Hoc Reviewer (1998–present)
  • Journal of Acquired Immunodeficiency Syndromes; Ad Hoc Reviewer (1998–present)
  • Journal of Autoimmunity; Ad Hoc Reviewer (1998–present)
  • Journal of Clinical Gastroenterology; Ad Hoc Reviewer (1998–present)
  • Journal of European Medical Students` Association; Ad Hoc Reviewer (1998–present)
  • Journal of Experimental Medicine; Ad Hoc Reviewer (1998–present)
  • Journal of General Internal Medicine; Ad Hoc Reviewer (1998–present)
  • AIDS; Ad Hoc Reviewer (1998–present)
  • AIDS Patient Care STDS; Ad Hoc Reviewer (1998–present)
  • Alimentary Pharmacology and Therapeutics; Ad Hoc Reviewer (1998–present)
  • Journal of Hepatology; Ad Hoc Reviewer (1998–present)
  • Journal of Infectious Diseases; Ad Hoc Reviewer (1998–present)
  • Journal of Medical Virology; Ad Hoc Reviewer (1998–present)
  • Journal of Substance Abuse Treatment; Ad Hoc Reviewer (1998–present)
  • Journal of Urban Health; Ad Hoc Reviewer (1998–present)
  • Liver International; Ad Hoc Reviewer (1998–present)
  • Nature Biotechnology; Ad Hoc Reviewer (1998–present)
  • PloS ONE; Ad Hoc Reviewer (1998–present)
  • American Journal of Gastroenterology; Ad Hoc Reviewer (1998–present)
  • American Journal of Pathology; Ad Hoc Reviewer (1998–present)
  • Annals of Internal Medicine; Ad Hoc Reviewer (1998–present)
  • Clinical Infectious Diseases; Ad Hoc Reviewer (1998–present)
  • Science Translational Medicine; Ad Hoc Reviewer (1998–present)
  • The AIDS Reader; Ad Hoc Reviewer (1998–present)
  • Translational Research; Ad Hoc Reviewer (1998–present)

School News:

In the Media:

Clinical Specialties:

Clinical Offices:

Insurance Accepted:

Contact Information

Clinical and Translational Research Center
875 Ellicott Street
Suite 6090
Buffalo, New York 14203
Phone: 716-961-9900
Fax: 716-854-1397
ahtalal@buffalo.edu
View map
View faculty website

This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.

View this physician on UBMD
Login to Update Your Profile